DK167905B1 - Farmaceutiske praeparater interferon, dacarbazin og en ornithin-decarboxylase-inhibitor til behandling af maligne melanomaer - Google Patents

Farmaceutiske praeparater interferon, dacarbazin og en ornithin-decarboxylase-inhibitor til behandling af maligne melanomaer Download PDF

Info

Publication number
DK167905B1
DK167905B1 DK222988A DK222988A DK167905B1 DK 167905 B1 DK167905 B1 DK 167905B1 DK 222988 A DK222988 A DK 222988A DK 222988 A DK222988 A DK 222988A DK 167905 B1 DK167905 B1 DK 167905B1
Authority
DK
Denmark
Prior art keywords
interferon
decarboxylase inhibitor
animal
treatment
melanomas
Prior art date
Application number
DK222988A
Other languages
Danish (da)
English (en)
Other versions
DK222988D0 (da
DK222988A (da
Inventor
Sai Prasad Sunkara
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of DK222988D0 publication Critical patent/DK222988D0/da
Publication of DK222988A publication Critical patent/DK222988A/da
Application granted granted Critical
Publication of DK167905B1 publication Critical patent/DK167905B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK222988A 1987-04-23 1988-04-22 Farmaceutiske praeparater interferon, dacarbazin og en ornithin-decarboxylase-inhibitor til behandling af maligne melanomaer DK167905B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189187A 1987-04-23 1987-04-23
US4189187 1987-04-23

Publications (3)

Publication Number Publication Date
DK222988D0 DK222988D0 (da) 1988-04-22
DK222988A DK222988A (da) 1988-10-24
DK167905B1 true DK167905B1 (da) 1994-01-03

Family

ID=21918900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK222988A DK167905B1 (da) 1987-04-23 1988-04-22 Farmaceutiske praeparater interferon, dacarbazin og en ornithin-decarboxylase-inhibitor til behandling af maligne melanomaer

Country Status (11)

Country Link
EP (1) EP0288055B1 (enExample)
JP (1) JPS63280019A (enExample)
KR (1) KR880012239A (enExample)
AT (1) ATE78174T1 (enExample)
AU (1) AU609120B2 (enExample)
DE (1) DE3872749T2 (enExample)
DK (1) DK167905B1 (enExample)
ES (1) ES2051788T3 (enExample)
GR (1) GR3005553T3 (enExample)
IE (1) IE61498B1 (enExample)
ZA (1) ZA882719B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
IL97759A0 (en) * 1990-04-11 1992-06-21 Ciba Geigy Ag Hydroxylamine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Also Published As

Publication number Publication date
GR3005553T3 (enExample) 1993-06-07
IE881221L (en) 1988-10-23
DK222988D0 (da) 1988-04-22
IE61498B1 (en) 1994-11-02
EP0288055B1 (en) 1992-07-15
AU609120B2 (en) 1991-04-26
ZA882719B (en) 1988-10-17
EP0288055A1 (en) 1988-10-26
AU1502388A (en) 1988-10-27
DK222988A (da) 1988-10-24
DE3872749D1 (de) 1992-08-20
KR880012239A (ko) 1988-11-26
ATE78174T1 (de) 1992-08-15
DE3872749T2 (de) 1992-12-03
ES2051788T3 (es) 1994-07-01
JPS63280019A (ja) 1988-11-17

Similar Documents

Publication Publication Date Title
US4499072A (en) Process for treating diseases with ODC inhibitors
Woodman et al. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1, 2-bis (3, 5-dioxopiperazine-1-yl) propane or several other antitumor agents
CA2151826C (en) Pharmaceutical compositions for prevention and treatment of cancerous diseases and process for their preparation
EP0610444B1 (en) Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases
JPH09501411A (ja) 抗−新生物組成物及びその使用方法
US20040235755A1 (en) Use of amino acids amino acid alogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
JPH06511473A (ja) 造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体
NL8100579A (nl) Toepassing van nooetroop werkzame verbindingen.
US6525035B1 (en) Therapeutic composition and methods
Warrington et al. Histidinol-mediated Improvement in the Specificity of 1-β-d-Arabinofuranosylcytosine and 5-Fluorouracil in L1210 Leukemia-bearing Mice
AU609120B2 (en) Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma
EP0248217B1 (en) Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with lak cells and interleukin-2, of tumors
KR100457113B1 (ko) 세라마이드류 또는 그 유도체와 다이메틸스핑고신을 유효성분으로 포함하는 방사선민감도 증진제
FR2600252A1 (fr) Medicament et composition medicamenteuse pour le traitement de maladies infectieuses dues aux virus, ainsi que pour le traitement des tumeurs
TW202019440A (zh) 用於治療癌症之組合療法
WO1991014432A1 (en) Supportive use
JPS59130213A (ja) 抗腫瘍方法及び組成物
Eleff et al. Analysis of" Early" Thymidine/Inosine Protection as an Adjunct to
RU2253446C1 (ru) Противоопухолевое средство
PH26698A (en) Method of potentiating natural killer cell activity
Chen et al. The Central Nervous Depressive Effect of Khellin
NL8001602A (nl) Nitrosoureumderivaten met anti-tumorwerkzaamheid, als- mede daarmee samengestelde farmaceutische samenstel- ling.
RU2068690C1 (ru) Способ лечения злокачественных новообразований
JPH0534338B2 (enExample)
Shuji et al. Alleviation of intestinal lesions by combined treatment with a 5-fluoro-2'-deoxyuridine (FUDR) derivative and α-Difluoromethylornithine (DMFO) in tumor-bearing mice

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK